Vaxart, Inc. (VXRT) stock dropped by 25% over the past month. Vaxart is a competitor too for COVID-19 vaccine, but its vaccine that is administered by tablet rather than by injection, or called it oral recombinant vaccine.
However, the company's oral COVID-19 vaccine candidate, VXA-CoV2-1 is progressing slowly, it may be related to the company's strategy. The company said in its Q4 and FY 2020 financial results that a better solution is needed given that COVID-19 may be a challenge for years to come. It seems that the company thinks of its VXA-CoV2-1 as a long term strategy investment. So, the company's oral vaccine will not appear on the market in the short term. This may be main reason that investors have lost their interest on this stock.
But this stock is worth to track for investors. The company currently has enough cash to advance its clinical trials on this oral vaccine. The company plans to initiate the first Phase 2 study of VXA-CoV2-1 in 2Q 2021. If the company comes out with clinical results that show its oral vaccine can achieve high efficacy, then the company still has a chance to win the market.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.